Roberts labs Radinyl (etanidazole)
Roberts labs Radinyl (etanidazole): DuPont acquires North American marketing rights to the radiosensitizer agent. The new class of drugs has no direct chemotherapeutic effect but rather enhances the ability of radiation to kill cancer cells. Etanidazole was developed by the Stanford Research Institute under a grant from NCI. The products in in Phase II/III clinicals in the U.S. under sponsorship of NCI, while Roberts is funding trials in Europe. Roberts will submit the NDA in the U.S.
You may also be interested in...
If President Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsberg, Affordable Care Act coverage could disappear. See what Kyle Sampson, a partner with the Washington, DC law firm King & Spalding said about it here.
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.